Ingredion/$INGR
Ingredion shares fall as Q3 operating income declined 19% and the company cut FY26 earnings guidance, citing a slower North American recovery, higher input costs and softer demand.
21 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Ingredion
Ingredion is an ingredients provider for the food, beverage, brewing, and animal nutrition industries. The company processes corn, tapioca, potatoes, stevia, grains, fruits, gums, and vegetables into value-added ingredients. The company sells specialty ingredients that include starch-based texturizers and natural alternative sweeteners such as stevia. Ingredion also sells commodity ingredients that include sweeteners, such as high-fructose corn syrup, and starches, such as those used for sustainable packaging, as well as plant-based proteins. The company plans to acquire Tate & Lyle in an all-cash deal that should close in 2027.
- Ticker
- $INGR
- Sector
- Consumer Essentials
- Primary listing
- NYSE
- Employees
- 11,000
- Headquarters
- Westchester, United States
- Website
- www.ingredion.com
Ingredion Metrics
BasicAdvanced
$5.7B
10.41
$8.81
0.62
$3.29
3.62%
Price and volume
Market cap
$5.7B
Beta
0.62
52-week high
$123.49
52-week low
$90.19
Average daily volume
791K
Dividend rate
$3.29
Financial strength
Current ratio
2.007
Quick ratio
1.318
Long term debt to equity
0.273
Total debt to equity
0.39
Dividend payout ratio (TTM)
37.66%
Interest coverage (TTM)
11.09%
Profitability
EBITDA (TTM)
1,087
Gross margin (TTM)
23.03%
Net profit margin (TTM)
7.83%
Operating margin (TTM)
12.03%
Effective tax rate (TTM)
26.10%
Revenue per employee (TTM)
$650,000
Management effectiveness
Return on assets (TTM)
6.77%
Return on equity (TTM)
12.90%
Valuation
Price to earnings (TTM)
10.412
Price to revenue (TTM)
0.807
Price to book
1.26
Price to tangible book (TTM)
1.73
Price to free cash flow (TTM)
16.732
Free cash flow yield (TTM)
5.98%
Free cash flow per share (TTM)
5.482
Dividend yield (TTM)
3.59%
Forward dividend yield
3.62%
Growth
Revenue change (TTM)
-0.98%
Earnings per share change (TTM)
-12.02%
3-year revenue growth (CAGR)
-4.38%
10-year revenue growth (CAGR)
2.33%
3-year earnings per share growth (CAGR)
-1.94%
10-year earnings per share growth (CAGR)
2.76%
3-year dividend per share growth (CAGR)
4.18%
10-year dividend per share growth (CAGR)
5.93%
What the Analysts think about Ingredion
Analyst ratings (Buy, Hold, Sell) for Ingredion stock.
Analyst projections of the future price of Ingredion stock.
Bulls say / Bears say
Texture & Healthful Solutions has a growth engine: volumes rose for the tenth straight quarter, with clean-label sales up 8% year to date and share gains in strategic categories. This suggests customers continue to adopt higher-value ingredients even as the wider food market softens. (Ingredion Incorporated)
The pending Tate & Lyle deal could broaden Ingredion’s specialty ingredients range and customer reach, with about $130 million of annual cost synergies expected by 2030 and adjusted EPS accretion expected in the first year after completion. Several regulatory clearances have already been secured, although approvals remain outstanding in other jurisdictions. (Ingredion Incorporated, MLex)
LATAM demand is holding up: stronger brewing and beverage volumes in Mexico and Brazil supported Ingredion’s third-quarter sales activity. This gives the company a source of growth beyond its clean-label business. (Ingredion Incorporated)
Argo’s recovery is behind schedule: higher manufacturing costs and lower U.S./Canada volumes drove the segment’s third-quarter operating income down by $29 million year on year to $52 million. Ingredion now expects the segment’s 2026 operating income to fall 35–40%. (Ingredion Incorporated)
Input-cost inflation is squeezing specialty margins: Ingredion said tapioca costs were about 65% higher year on year, while Texture & Healthful Solutions operating income fell 9% excluding foreign-exchange effects. Price recovery typically takes about a quarter, leaving profits exposed while costs remain high. (The Motley Fool, Ingredion Incorporated)
The Tate & Lyle purchase brings financing and execution risk: S&P expects pro forma debt to EBITDA of 3.5x, with leverage reduction dependent on post-deal cash generation. The deal still needs regulatory clearance in several jurisdictions, so completion and the expected benefits are not yet certain. (S&P Global Ratings, MLex)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
Ingredion Financial Performance
Revenues and expenses
Ingredion Earnings Performance
Company profitability
Upcoming events
No upcoming events
Ingredion News
AllArticlesVideos
Funds containing Ingredion
AllUSDEURGBP
Fund name | Fund size | $INGR weighting |
|---|---|---|
SPDR S&P 400 US Mid Cap$SPY4 | $6.4B | 0.19% |
SPDR S&P 400 US Mid Cap£SPX4 | $6.4B | 0.19% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.18% |
iShares MSCI World Small Cap€IUSN | $9B | 0.06% |
iShares MSCI World Small Cap$WSML | $9B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.